Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to develop and commercialize DARPin in the radioligand therapy field. The parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
